PF-Atlas › Clinical Trials › NCT07333183

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

inhaled mosliciguat · Phase 2

Registry ID
NCT07333183
Phase
Phase 2
Status
Recruiting
Drug / intervention
inhaled mosliciguat
Sponsor
Pulmovant, Inc.
Start
2025-12-23
Enrollment
20
Locations
1

About this trial

This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.

View NCT07333183 on ClinicalTrials.gov →

Explore related

All inhaled mosliciguat trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT07333183 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.